Biofrontera to Participate in Upcoming Investor Conferences

Leverkusen, Germany, November 22, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its participation at the following events:

Event: Deutsches Eigenkapitalforum / Analyst conference
Format: Presentation & 1x1 Meetings
Date: Monday, November 25, 2019
Time: 5:00pm CET
Location: Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt/Main, Germany

Event: Benchmark Discovery 1x1 Conference
Format: 1x1 Meetings
Date: Wednesday, December 4, 2019
Location: The New York Athletic Club, New York, NY

Event: 12^th Annual LD Micro Main Event
Format: Presentation & 1x1 Meetings
Date: Wednesday, December 11, 2019
Time: 10:00am PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track 2
-End-

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz^(R), a topical prescription drug, and medical device BF-RhodoLED^(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz^(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi^TM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos^(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.